268 related articles for article (PubMed ID: 32740973)
21. Isocitrate Dehydrogenase-Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes.
Wintheiser G; Zemla T; Shi Q; Tran N; Prasai K; Tella SH; Mody K; Ahn D; Borad M; Bekaii-Saab T; Mahipal A
JCO Precis Oncol; 2022 Jan; 6():e2100156. PubMed ID: 35005992
[TBL] [Abstract][Full Text] [Related]
22. Ten-eleven translocation protein 1 modulates medulloblastoma progression.
Kim H; Kang Y; Li Y; Chen L; Lin L; Johnson ND; Zhu D; Robinson MH; McSwain L; Barwick BG; Yuan X; Liao X; Zhao J; Zhang Z; Shu Q; Chen J; Allen EG; Kenney AM; Castellino RC; Van Meir EG; Conneely KN; Vertino PM; Jin P; Li J
Genome Biol; 2021 Apr; 22(1):125. PubMed ID: 33926529
[TBL] [Abstract][Full Text] [Related]
23. Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the BET inhibitor JQ1.
Fujiwara H; Tateishi K; Kato H; Nakatsuka T; Yamamoto K; Tanaka Y; Ijichi H; Takahara N; Mizuno S; Kogure H; Matsubara S; Nakai Y; Koike K
Cancer Sci; 2018 Nov; 109(11):3602-3610. PubMed ID: 30156013
[TBL] [Abstract][Full Text] [Related]
24. Ivosidenib for the treatment of isocitrate dehydrogenase-1 mutant cholangiocarcinoma.
Corrigan L; Lowery M
Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):475-481. PubMed ID: 33836133
[No Abstract] [Full Text] [Related]
25. Platinum sensitivity in patients with IDH1/2 mutated vs wild-type intrahepatic cholangiocarcinoma: A propensity score-based study.
Niger M; Nichetti F; Casadei-Gardini A; Rizzato MD; Pircher C; Bini M; Franza A; Rimini M; Burgio V; Sposetti C; Fornaro L; Rapposelli IG; D'Amico FE; Aprile G; Vivaldi C; Frassineti GL; Milione M; Leoncini G; Cappetta A; Vasile E; Fassan M; Morano F; Perrone F; Tamborini E; Pruneri G; Lonardi S; Mazzaferro V; Pietrantonio F; Di Bartolomeo M; de Braud F
Int J Cancer; 2022 Oct; 151(8):1310-1320. PubMed ID: 35723131
[TBL] [Abstract][Full Text] [Related]
26. BMI1 promotes cholangiocarcinoma progression and correlates with antitumor immunity in an exosome-dependent manner.
Liu Z; Hu C; Zheng L; Liu J; Li K; Li X; Wang Y; Mu W; Chen T; Shi A; Qiu B; Zhang X; Zhang Z; Xu Y
Cell Mol Life Sci; 2022 Aug; 79(9):469. PubMed ID: 35932322
[TBL] [Abstract][Full Text] [Related]
27. Reduced ten-eleven translocation and isocitrate dehydrogenase expression in inflammatory hidradenitis suppurativa lesions.
Hessam S; Gambichler T; Skrygan M; Sand M; Rüddel I; Scholl L; Bechara FG
Eur J Dermatol; 2018 Aug; 28(4):449-456. PubMed ID: 30325321
[TBL] [Abstract][Full Text] [Related]
28. Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions.
Lavacchi D; Caliman E; Rossi G; Buttitta E; Botteri C; Fancelli S; Pellegrini E; Roviello G; Pillozzi S; Antonuzzo L
Pharmacol Ther; 2022 Sep; 237():108170. PubMed ID: 35296436
[TBL] [Abstract][Full Text] [Related]
29. YAP is a critical oncogene in human cholangiocarcinoma.
Pei T; Li Y; Wang J; Wang H; Liang Y; Shi H; Sun B; Yin D; Sun J; Song R; Pan S; Sun Y; Jiang H; Zheng T; Liu L
Oncotarget; 2015 Jul; 6(19):17206-20. PubMed ID: 26015398
[TBL] [Abstract][Full Text] [Related]
30. Gankyrin promotes tumor growth and metastasis through activation of IL-6/STAT3 signaling in human cholangiocarcinoma.
Zheng T; Hong X; Wang J; Pei T; Liang Y; Yin D; Song R; Song X; Lu Z; Qi S; Liu J; Sun B; Xie C; Pan S; Li Y; Luo X; Li S; Fang X; Bhatta N; Jiang H; Liu L
Hepatology; 2014 Mar; 59(3):935-46. PubMed ID: 24037855
[TBL] [Abstract][Full Text] [Related]
31. Mutations of isocitrate dehydrogenase 1 and 2 in intrahepatic cholangiocarcinoma.
Grassian AR; Pagliarini R; Chiang DY
Curr Opin Gastroenterol; 2014 May; 30(3):295-302. PubMed ID: 24569570
[TBL] [Abstract][Full Text] [Related]
32. Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma.
Peraldo-Neia C; Ostano P; Cavalloni G; Pignochino Y; Sangiolo D; De Cecco L; Marchesi E; Ribero D; Scarpa A; De Rose AM; Giuliani A; Calise F; Raggi C; Invernizzi P; Aglietta M; Chiorino G; Leone F
BMC Genomics; 2018 Jun; 19(1):440. PubMed ID: 29871612
[TBL] [Abstract][Full Text] [Related]
33. Modulation of ten-eleven translocation 1 (TET1), Isocitrate Dehydrogenase (IDH) expression, α-Ketoglutarate (α-KG), and DNA hydroxymethylation levels by interleukin-1β in primary human chondrocytes.
Haseeb A; Makki MS; Haqqi TM
J Biol Chem; 2014 Mar; 289(10):6877-6885. PubMed ID: 24469454
[TBL] [Abstract][Full Text] [Related]
34. Profiling of downregulated blood-circulating miR-150-5p as a novel tumor marker for cholangiocarcinoma.
Wu X; Xia M; Chen D; Wu F; Lv Z; Zhan Q; Jiao Y; Wang W; Chen G; An F
Tumour Biol; 2016 Nov; 37(11):15019-15029. PubMed ID: 27658773
[TBL] [Abstract][Full Text] [Related]
35.
Crispo F; Pietrafesa M; Condelli V; Maddalena F; Bruno G; Piscazzi A; Sgambato A; Esposito F; Landriscina M
Molecules; 2020 Aug; 25(16):. PubMed ID: 32824685
[TBL] [Abstract][Full Text] [Related]
36. Upregulated microRNA-194 impairs stemness of cholangiocarcinoma cells through the Rho pathway via inhibition of ECT2.
Gao J; Dai C; Yu X; Yin XB; Zhou F
J Cell Biochem; 2020 Oct; 121(10):4239-4250. PubMed ID: 31960990
[TBL] [Abstract][Full Text] [Related]
37. CAPS1 Suppresses Tumorigenesis in Cholangiocarcinoma.
Weng S; Janssen HLA; Zhang N; Tang W; Bai E; Yang B; Dong L
Dig Dis Sci; 2020 Apr; 65(4):1053-1063. PubMed ID: 31562609
[TBL] [Abstract][Full Text] [Related]
38. The SIRT2/cMYC Pathway Inhibits Peroxidation-Related Apoptosis In Cholangiocarcinoma Through Metabolic Reprogramming.
Xu L; Wang L; Zhou L; Dorfman RG; Pan Y; Tang D; Wang Y; Yin Y; Jiang C; Zou X; Wu J; Zhang M
Neoplasia; 2019 May; 21(5):429-441. PubMed ID: 30933885
[TBL] [Abstract][Full Text] [Related]
39. Distinct clinical and prognostic implication of IDH1/2 mutation and other most frequent mutations in large duct and small duct subtypes of intrahepatic cholangiocarcinoma.
Ma B; Meng H; Tian Y; Wang Y; Song T; Zhang T; Wu Q; Cui Y; Li H; Zhang W; Li Q
BMC Cancer; 2020 Apr; 20(1):318. PubMed ID: 32293336
[TBL] [Abstract][Full Text] [Related]
40. Sirtuin7 has an oncogenic potential via promoting the growth of cholangiocarcinoma cells.
Li W; Sun Z; Chen C; Wang L; Geng Z; Tao J
Biomed Pharmacother; 2018 Apr; 100():257-266. PubMed ID: 29438839
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
